Pharmacoeconomic analysis of luteinizing hormone — releasing hormone analogues use in prostate cancer patients (2016)

Summary. Complex pharmacoeconomic analysis of luteinizing hormone — releasing hormone analogues presented in Ukrainian pharmaceutical market in the I quarter of 2016 was performed. Essential economic advantages of drugs of the above group with due regard for efficiency and price changes comparing with similar study completed in 2014 were determined. The analysis of sensitivity confirms the results received in complex pharmacoeconomic analysis of 2014, notably significant economic advantage of all three forms of leuprorelin (7.5 mg, 22.5 mg and 45 mg) to compare whith the analogues.